Skip to main content
. 2005 Jun;79(12):7777–7784. doi: 10.1128/JVI.79.12.7777-7784.2005

TABLE 2.

Susceptibility of selected and gp160-recombined HIV-1 strains to the inhibitory effect of various antiviral compounds

Compound EC50a(μg/ml) (fold increase)b
WT strains
Strains resistant to CV-N
Strains resistant to ConA
Strains with mutated gp120
HIV-1(NL4.3) R160/NL4.3c NL4.3/CV-Nresd R160/CV-Nrese NL4.3/ConAresd R160/ConArese HIV-1(N302K)
Carbohydrate binding inhibitors
    CV-N 0.004 ± 0.002 0.003 ± 0.001 0.6 ± 0.3 (143) 0.2 ± 0.01 (77) 0.6 ± 0.4 (156) 0.006 ± 0.002 (1.4)
    ConA 2.6 ± 1.4 2.2 ± 0.06 >22.7 ± 1.3 (>8.8) >23.9 ± 1.0 (>9.3) >21.5 ± 0.8 (>9.7) >2.2 ± 0.4 (>0.9)
    2G12 0.9 ± 0.2 1.0 ± 0.1 >40 (>43.0) >40 (>40.0) >40 (>46.1) >40 (>40.0) >40 (>43.0)
Reference compounds
    AMD3100 0.02 ± 0.01 0.01 ± 0.008 0.03 ± 0.01 (1.3) 0.02 ± 0.02 (1.4) 0.03 ± 0.01 (1.5) 0.02 ± 0.02 (1.7) 0.009 ± 0.0002 (0.5)
    Enfuvirtide 2.1 ± 1.1 1.5 ± 0.7 3.6 ± 0.9 (1.7) 2.7 ± 0.8 (1.8) 3.8 ± 0.3 (1.8) 3.8 ± 0.7 (2.6) 2.2 (1.1)
    Zidovudine 0.0006 ± 0.0003 0.0005 ± 0.0002 0.001 ± 0.0004 (1.8) 0.001 ± 0.0003 (2.6) 0.001 ± 0.0004 (2.2) 0.001 ± 0.0004 (2.8) 0.0004 ± 0.0002 (0.6)
    Ritonavir 0.03 ± 0.007 0.03 ± 0.002 0.04 ± 0.02 (1.4) 0.03 ± 0.001 (1.2) 0.04 ± 0.01 (1.4) 0.04 ± 0.007 (1.4) 0.02 ± 0.002 (0.6)
a

50% effective concentration (EC50) or concentration required to inhibit the CPE of different HIV strains by 50% in MT-4 cells.

b

Fold increase in the EC50 of the compound for in vitro-selected HIV-1(NL4.3) or the recombined selected strain compared to the EC50 of the compound for the parental HIV-1(NL4.3) strain or the recombined HIV-1(NL4.3) strain, respectively.

c

HIV-1(NL4.3) wild-type strain recombined with the gp160 gene of pNL4.3.

d

HIV-1(NL4.3) strain selected in vitro in the presence of CV-N or ConA.

e

HIV-1(NL4.3) wild-type strain recombined with the gp160 gene of the respective selected HIV-1(NL4.3) strain.